中科微点-全球专利检索

  1. Login
  2. Sign Up

Search Results

52 records (took 0.024 seconds)

    PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY
    11.
    发明申请
    PEPTIDE COMPOUNDS AND PEPTIDE CONJUGATES FOR THE TREATMENT OF CANCER THROUGH RECEPTOR-MEDIATED CHEMOTHERAPY 有权

    公开(公告)号：US20220356209A1

    公开(公告)日：2022-11-10

    申请号：US17239544

    申请日：2021-04-23

    Applicant: TRANSFERT PLUS, S.E.C.

    Inventor： Richard BÉLIVEAU ,  Borhane ANNABI ,  Michel DEMEULE ,  Alain LAROCQUE ,  Jean-Christophe CURRIE ,  Cyndia CHARFI

    IPC: C07K7/08 ,  A61K47/64 ,  A61P35/00 ,  A61K31/337 ,  C07K1/06 ,  C07K14/00

    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treating cancer. For example, the compounds can comprise compounds of formula X1X2X3X4X5GVX6AKAGVX7NX8FKSESY
    (I)
    (SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY
    (II)
    (SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L
    (III)
    (SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L
    (IV)
    (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM
    (V)
    (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY
    (VI)
    (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK
    (VII)
    (SEQ ID NO: 7) GVQAKAGVINMFKSESY
    (VIII)
    (SEQ ID NO: 8) GVRAKAGVRNMFKSESY
    (IX)
    (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY
    (X)
    (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL
    (XI)
    (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL
    (XII)
    (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL
    (XIII)
    (SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end.

    METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY
    12.
    发明申请
    METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY 有权

    公开(公告)号：US20220000971A1

    公开(公告)日：2022-01-06

    申请号：US17270787

    申请日：2019-08-26

    Applicant: TRANSFERT PLUS, S.E.C.

    Inventor： Richard BÉLIVEAU ,  Borhane ANNABI ,  Michel DEMEULE ,  Alain LAROCQUE ,  Jean-Christophe CURRIE ,  Alain ZGHEIB

    IPC: A61K38/16 ,  A61K47/64 ,  A61P35/00

    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X1X2X3X4X5GVX6AKAGVX7NX8FKSESY (I) (SEQ ID NO: 1) (X9)nGVX10AKAGVX11NX12FKSESY (II) (SEQ ID NO: 2) YKX13LRRX14APRWDX15PLRDPALRX16X17L (III) (SEQ ID NO: 3) YKX18LRR(X19)nPLRDPALRX20X21L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X1 to X21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end, for use in inhibiting vasculogenic mimicry and/or for treating a cancer.

    P97 protein and uses thereof as vaccine adjuvant
    13.
    发明授权
    P97 protein and uses thereof as vaccine adjuvant 有权
    P97蛋白及其作为疫苗佐剂的用途

    公开(公告)号：US09028828B2

    公开(公告)日：2015-05-12

    申请号：US13872503

    申请日：2013-04-29

    Applicant: Transfert Plus, S.E.C.

    Inventor： Denis Archambault ,  Elodie Roques

    IPC: C07K14/30 ,  C07K14/00

    CPC classification number: C07K14/001 ,  C07K14/30

    Abstract: Immunogenic compositions comprising a p97 adhesin adjuvant polypeptide, or a nucleic acid encoding said p97 adhesin adjuvant polypeptide, and a heterologous antigen are disclosed. Uses of the p97 adhesin adjuvant polypeptide or nucleic acid, or immunogenic compositions comprising same, for inducing an immune response against a heterologous antigen in a subject are also disclosed.

    Abstract translation: 公开了包含p97粘附素佐剂多肽或编码所述p97粘附素佐剂多肽的核酸和异源抗原的免疫原性组合物。 还公开了p97粘附素佐剂多肽或核酸或包含其的免疫原性组合物用于诱导受试者中异源抗原的免疫应答的用途。

    METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY
    14.
    发明申请
    METHODS AND COMPOUNDS FOR TARGETING SORTILIN RECEPTORS AND INHIBITING VASCULOGENIC MIMICRY 审中-公开

    公开(公告)号：WO2020037434A1

    公开(公告)日：2020-02-27

    申请号：PCT/CA2019/051170

    申请日：2019-08-26

    Applicant: TRANSFERT PLUS, S.E.C.

    Inventor： BÉLIVEAU, Richard ,  ANNABI, Borhane ,  DEMEULE, Michel ,  LAROCQUE, Alain ,  CURRIE, Jean-christophe ,  ZGHEIB, Alain

    IPC: C07K16/28 ,  A61K47/64 ,  A61K47/68 ,  A61P35/00 ,  A61P9/00 ,  C07K14/00 ,  C07K14/705 ,  C07K16/18 ,  C07K7/08 ,  C40B30/04

    Abstract: The present disclosure relates to peptide compounds and conjugate compounds, processes, methods and uses thereof for treatment of cancer or aggressive cancer. For example, the compounds can comprise compounds of formula X 1 X 2 X 3 X 4 X 5 GVX 6 AKAGVX 7 NX 8 FKSESY (I) (SEQ ID NO: 1) (X 9 ) n GVX 10 AKAGVX 11 NX 12 FKSESY (II) (SEQ ID NO: 2) YKX 13 LRRX 14 APRWDX 15 PLRDPALRX 16 X 17 L (III) (SEQ ID NO: 3) YKX 18 LRR(X 19 ) n PLRDPALRX 20 X 21 L (IV) (SEQ ID NO: 4) IKLSGGVQAKAGVINMDKSESM (V) (SEQ ID NO: 5) IKLSGGVQAKAGVINMFKSESY (VI) (SEQ ID NO: 6) IKLSGGVQAKAGVINMFKSESYK (VII) (SEQ ID NO: 7) GVQAKAGVINMFKSESY (VIII) (SEQ ID NO: 8) GVRAKAGVRNMFKSESY (IX) (SEQ ID NO: 9) GVRAKAGVRN(Nle)FKSESY (X) (SEQ ID NO: 10) YKSLRRKAPRWDAPLRDPALRQLL (XI) (SEQ ID NO: 11) YKSLRRKAPRWDAYLRDPALRQLL (XII) (SEQ ID NO: 12) YKSLRRKAPRWDAYLRDPALRPLL (XIII) (SEQ ID NO: 13) wherein X 1 to X 21 and n can have various different values and wherein at least one protecting group and/or at least one labelling agent is optionally connected to said peptide compound at an N- and/or C-terminal end, for use in inhibiting vasculogenic mimicry and/or for treating a cancer.

    PROCESS FOR PREPARING SULFONYLIMIDES AND DERIVATIVES THEREOF
    19.
    发明申请
    PROCESS FOR PREPARING SULFONYLIMIDES AND DERIVATIVES THEREOF 审中-公开
    制备磺酰亚胺及其衍生物的方法

    公开(公告)号：WO2007022624A1

    公开(公告)日：2007-03-01

    申请号：PCT/CA2006/001373

    申请日：2006-08-21

    Applicant: TRANSFERT PLUS, S.E.C. ,  HAMMAMI, Amer ,  MARSAN, Benoît

    Inventor： HAMMAMI, Amer ,  MARSAN, Benoît

    IPC: C07C311/48 ,  C07C303/36

    CPC classification number: C01B21/0935 ,  C01B21/086 ,  C07C311/48

    Abstract: The present invention relates to the field of sulfonylimides and derivatives thereof Pn particular, it relates to processes for preparing compounds of formula (I) wherein each of the R 1 groups is independently F, Cl, Br or I, and R 2 is H, Li, Na, K or Cs The processes are useful for preparing compounds used in the field of electrochemistry, particularly in the production of lithium batteries and solar cells The present invention also relates to intermediates of the compounds of formula (I)

    Abstract translation: 本发明涉及磺酰亚胺及其衍生物的领域。特别地，本发明涉及制备式（I）化合物的方法，其中R 1和R 2各自独立地为F，Cl，Br或I ，R 2是H，Li，Na，K或Cs。这些方法可用于制备电化学领域中使用的化合物，特别是在锂电池和太阳能电池的生产中。本发明还涉及 到式（I）化合物的中间体，

Patent Agency Ranking